Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Article in English | WPRIM | ID: wpr-758926

ABSTRACT

Cystic endometrial hyperplasia-pyometra complex (CEH/P) is a challenge in canine reproduction. Present study aimed to assess fertility after medical treatment. One-hundred-seventy-four bitches affected by CEH/P received aglepristone on days 1, 2, 8, then every 7 days until blood progesterone < 1.2 ng/mL; cloprostenol was administered on days 3 to 5. Records were grouped according to bodyweight (BW): small (< 10 kg, n = 33), medium (10 ≥ BW < 25 kg, n = 44), large (25 ≥ BW < 40 kg, n = 52), and giant bitches (BW ≥ 40 kg, n = 45). Age; success rate; aglepristone treatments number; relapse, pregnancy rates; diagnosis-relapse,


Subject(s)
Animals , Cloprostenol , Dogs , Fertility , Pregnancy , Pregnancy Rate , Progesterone , Pyometra , Recurrence , Reproduction
2.
Arq. bras. med. vet. zootec. (Online) ; 69(4): 821-829, jul.-ago. 2017. tab, graf
Article in English | LILACS, VETINDEX | ID: biblio-876523

ABSTRACT

The present study investigated the hormonal profile and expression of prostaglandin F2α (PGF2α), oxytocin and estrogen receptors in uterine tissues of postpartum cows treated with cloprostenol. Twenty Holstein-Zebu crossbred cows were treated with saline solution (treatment CONT) or cloprostenol (treatment CLO), both administered two and five days postpartum. Blood samples were collected on days two, seven, 14, 21 and 28 postpartum for progesterone, PGF2α metabolite (PGFM) and estradiol determination, and endometrial biopsy was performed in order to quantify the expression of oxytocin receptor (OXTR), prostaglandin F receptor (PTGFR) and estrogen receptor 1 (ERS1) genes. In the CLO treatment, expression of OXTR was reduced (P<0.05) but no difference (P>0.05) between treatments was found for PTGFR and ERS1 expression. Estrogen concentrations increased progressively until day 14 (P<0.05) and the highest OXTR expression and lowest PTGFR expression were observed on day 14 (P<0.05) in both treatments. Serum PGFM concentrations were high throughout the experiment. In conclusion, cloprostenol administration at days two and five of postpartum seems to reduce OXTR expression in the endometrium in crossbred cows.(AU)


O presente estudo avaliou o perfil hormonal e a expressão gênica de receptores de prostaglandina F2α (PGF2α), ocitocina e estrógeno no endométrio de vacas pós-parto tratadas com cloprostenol. Vinte vacas mestiças Holandês-Zebu foram tratadas com solução salina (tratamento CONT, n = 10) ou cloprostenol (tratamento CLO, n = 10), ambos administrados dois e cinco dias após o parto. Amostras de sangue foram coletadas nos dias dois, sete, 14, 21 e 28 pós-parto para mensuração de progesterona, de metabólito de PGF2α (PGFM) e de estradiol, e foram obtidas biópsias endometriais para quantificar a expressão de PTGFR, OXTR e ESR1. No tratamento CLO, a expressão gênica de receptores de ocitocina foi menor (P<0,05). As concentrações de estrógeno aumentaram progressivamente até o dia 14 (P<0,05). A maior expressão de OXTR foi observada no dia 14 (P<0,05). A expressão de ESR1 foi semelhante entre os tratamentos (P>0,05). Os níveis de PGFM foram altos durante todo o estudo. Conclui-se que a administração de cloprostenol nos dias dois e cinco pós-parto parece diminuir a expressão de OXTR no endométrio em vacas mestiças.(AU)


Subject(s)
Animals , Female , Cattle , Cloprostenol/administration & dosage , Postpartum Period , Receptors, Oxytocin/analysis , Estradiol/analysis , Progesterone/analysis , Real-Time Polymerase Chain Reaction/veterinary , Receptors, Prostaglandin/analysis
3.
Chinese Medical Journal ; (24): 905-910, 2014.
Article in English | WPRIM | ID: wpr-253235

ABSTRACT

<p><b>BACKGROUND</b>Lowering intraocular pressure (IOP) is currently the only therapeutic approach in primary open-angle glaucoma. and the fixed-combination medications are needed to achieve sufficiently low target IOP. A multicenter prospective study in the Chinese population was needed to confirm the safety and efficacy of Bimatoprost/Timolol Fixed Combination Eye Drop in China. In this study, we evaluated the safety and efficacy of Bimatoprost/Timolol Fixed Combination with concurrent administration of its components in Chinese patients with open-angle glaucoma or ocular hypertension.</p><p><b>METHODS</b>In this multicenter, randomized, double-masked, parallel controlled study, patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy with either topical β-blockers or prostaglandin analogues were randomized to one of two active treatment groups in a 1:1 ratio at 11 Chinese ophthalmic departments. Bimatoprost/timolol fixed combination treatment was a fixed combination of 0.03% bimatoprost and 0.5% timolol (followed by vehicle for masking) once daily at 19:00 P.M. and concurrent treatment was 0.03% bimatoprost followed by 0.5% timolol once daily at 19:00 P.M. The primary efficacy variable was change from baseline in mean diurnal intraocular pressure (IOP) at week 4 visit in the intent-to-treat (ITT) population. Primary analysis evaluated the non-inferiority of bimatoprost/ timolol fixed combination to concurrent with respect to the primary variable using a confidence interval (CI) approach. Bimatoprost/timolol fixed combination was to be considered non-inferior to concurrent if the upper limit of the 95% CI for the between-treatment (bimatoprost/timolol fixed combination minus concurrent) difference was ≤ 1.5 mmHg. Adverse events were collected and slit-lamp examinations were performed to assess safety. Between-group comparisons of the incidence of adverse events were performed using the Pearson chi-square test or Fisher's exact test.</p><p><b>RESULTS</b>Of the enrolled 235 patients, 121 patients were randomized to receive bimatoprost/timolol fixed combination and, 114 patients were randomized to receive concurrent treatment. At baseline the mean value of mean diurnal IOP was (25.20 ± 3.06) mmHg in the bimatoprost/timolol fixed combination group and (24.87 ± 3.88) mmHg in the concurrent group. The difference between the treatment groups was not statistically significant. The mean change from baseline in mean diurnal IOP (± standard deviation) in the bimatoprost/timolol fixed combination group was (-9.38 ± 4.66) mmHg and it was (-8.93 ± 4.25) mmHg in the concurrent group (P < 0.01). The difference between the two treatment groups (bimatoprost/timolol fixed combination minus concurrent) in the change from baseline of mean diurnal IOP was -0.556 mmHg (95% CI: -1.68, 0.57, P = 0.330). The upper limit of the 95% CI was less than 1.5 mmHg, the predefined margin of non-inferiority. Adverse events occurred in 26.4% (32/121) of the bimatoprost/timolol fixed combination patients and 30.7% (35/114) of the concurrent patients. The most frequent adverse event was conjunctival hyperemia, which was reported as treatment related in 16.5% (20/121) in the bimatoprost/timolol fixed combination group and 18.4% (21/114) in the concurrent group (P > 0.05).</p><p><b>CONCLUSIONS</b>Bimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components. Safety profiles were similar between the treatment groups.</p>


Subject(s)
Adolescent , Adult , Aged , Amides , Therapeutic Uses , Bimatoprost , Cloprostenol , Therapeutic Uses , Female , Glaucoma, Open-Angle , Drug Therapy , Humans , Male , Middle Aged , Ocular Hypertension , Drug Therapy , Timolol , Therapeutic Uses , Young Adult
4.
Article in English | WPRIM | ID: wpr-143109

ABSTRACT

PURPOSE: To evaluate the effects of a bimatoprost/timolol fixed combination (BTFC) and a latanoprost/timolol fixed combination (LTFC) on diurnal intraocular pressure (IOP) and anterior ocular parameters in healthy subjects. METHODS: We enrolled 58 healthy subjects in this prospective clinical study. Thirty subjects were treated with BTFC and 28 subjects were treated with LTFC. IOP was measured every 2 hours except from 01:00 and 05:00. Axial length, corneal curvature, and anterior chamber depth were obtained using the IOL master at baseline and 24 hours later. Adverse events were assessed by patient interview and by slit lamp examination. RESULTS: The largest difference in IOP between treated and untreated eyes 8 hours after instillation was 1.67 mmHg in the BTFC group (p < 0.001). The largest difference in IOP between treated and untreated eyes 10 hours after instillation was 1.93 mmHg in the LTFC group (p < 0.001). For anterior ocular parameters such as axial length, corneal curvature, anterior chamber depth at baseline and 24 hours after instillation, there were no significant differences between the baseline and 24-hour values in either the BTFC or LTFC group. The most frequently occurring adverse event was conjunctival hyperemia, which was found in 33.3% (n = 10) of the BTFC group and 25.0% (n = 7) of the LTFC group (p = 0.486). CONCLUSIONS: BTFC and LTFC provided a significant reduction in IOP from baseline without changing any anterior ocular parameters. Our results provide a reference for monocular trials to assess the effect of eye drops in a clinical condition.


Subject(s)
Adult , Aged , Aged, 80 and over , Amides/administration & dosage , Antihypertensive Agents/administration & dosage , Circadian Rhythm/physiology , Cloprostenol/administration & dosage , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Follow-Up Studies , Glaucoma, Open-Angle/drug therapy , Healthy Volunteers , Humans , Intraocular Pressure/drug effects , Male , Middle Aged , Ophthalmic Solutions , Prospective Studies , Prostaglandins F, Synthetic/administration & dosage , Timolol/administration & dosage , Tonometry, Ocular , Treatment Outcome
5.
Article in English | WPRIM | ID: wpr-143104

ABSTRACT

PURPOSE: To evaluate the effects of a bimatoprost/timolol fixed combination (BTFC) and a latanoprost/timolol fixed combination (LTFC) on diurnal intraocular pressure (IOP) and anterior ocular parameters in healthy subjects. METHODS: We enrolled 58 healthy subjects in this prospective clinical study. Thirty subjects were treated with BTFC and 28 subjects were treated with LTFC. IOP was measured every 2 hours except from 01:00 and 05:00. Axial length, corneal curvature, and anterior chamber depth were obtained using the IOL master at baseline and 24 hours later. Adverse events were assessed by patient interview and by slit lamp examination. RESULTS: The largest difference in IOP between treated and untreated eyes 8 hours after instillation was 1.67 mmHg in the BTFC group (p < 0.001). The largest difference in IOP between treated and untreated eyes 10 hours after instillation was 1.93 mmHg in the LTFC group (p < 0.001). For anterior ocular parameters such as axial length, corneal curvature, anterior chamber depth at baseline and 24 hours after instillation, there were no significant differences between the baseline and 24-hour values in either the BTFC or LTFC group. The most frequently occurring adverse event was conjunctival hyperemia, which was found in 33.3% (n = 10) of the BTFC group and 25.0% (n = 7) of the LTFC group (p = 0.486). CONCLUSIONS: BTFC and LTFC provided a significant reduction in IOP from baseline without changing any anterior ocular parameters. Our results provide a reference for monocular trials to assess the effect of eye drops in a clinical condition.


Subject(s)
Adult , Aged , Aged, 80 and over , Amides/administration & dosage , Antihypertensive Agents/administration & dosage , Circadian Rhythm/physiology , Cloprostenol/administration & dosage , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Follow-Up Studies , Glaucoma, Open-Angle/drug therapy , Healthy Volunteers , Humans , Intraocular Pressure/drug effects , Male , Middle Aged , Ophthalmic Solutions , Prospective Studies , Prostaglandins F, Synthetic/administration & dosage , Timolol/administration & dosage , Tonometry, Ocular , Treatment Outcome
6.
Arq. bras. oftalmol ; 76(5): 309-310, set.-out. 2013. ilus
Article in English | LILACS | ID: lil-690611

ABSTRACT

Eighty-two-year-old patient with a pacemaker using warfarin due to arrhythmia and having an intraocular lens in the right eye, developed spontaneous hemorrhagic choroidal detachment one day after the use of combined preparation of 0.5% timolol maleate and 0.004% travoprost, due to primary open-angle glaucoma. Hemorrhagic detachment was detected by anterior and posterior segment examination, as well as B-scan ultrasonography. After the detachment, excessive increased intraocular pressure was controlled with oral carbonic anhydrase inhibitor, cycloplegic and steroid therapy. After four months, visual acuity was 20/20 and the intraocular pressure was under control with 0.5% timolol maleate and 1% brinzolamide. Controlled reduction of the intraocular pressure should be considered, particularly in older patients under anticoagulant therapy and that had undergone prior ocular surgery.


Paciente de oitenta e dois anos de idade com marca-passo e utilizando varfarina devido à arritmia cardíaca e com uma lente intraocular no olho direito, desenvolveu descolamento de hemorrágico espontâneo de coroide um dia após o uso de colírio combinado de maleato de timolol a 0,5% e travoprosta a 0,004%, devido ao glaucoma de ângulo aberto primário. O descolamento hemorrágico foi detectado por análise do segmento anterior e posterior, bem como ultrassonografia modo B. Após o descolamento, o aumento excessivo da pressão intraocular foi controlado por inibidor da anidrase carbônica via oral, terapia cicloplégica e esteroides. Após quatro meses, a acuidade visual era 20/20 e a pressão intraocular estava sob controle com o maleato de timolol a 0,5% e brinzolamida a 1%. A redução controlada da pressão intraocular deve ser considerada, especialmente em pacientes idosos sob terapia anticoagulante e que tinham sido submetidos à cirurgia ocular prévia.


Subject(s)
Aged, 80 and over , Humans , Male , Antihypertensive Agents/adverse effects , Choroid Hemorrhage/chemically induced , Choroid/injuries , Cloprostenol/analogs & derivatives , Timolol/adverse effects , Choroid Hemorrhage , Cloprostenol/adverse effects , Glaucoma/drug therapy , Intraocular Pressure/drug effects , Ophthalmic Solutions
7.
Clinics ; 68(10): 1318-1324, out. 2013. tab, graf
Article in English | LILACS | ID: lil-689986

ABSTRACT

OBJECTIVES: To compare ocular surface changes induced via glaucoma treatment in patients using fixed combinations of prostaglandin analogues (travoprost, latanoprost and bimatoprost) with 0.5% timolol maleate METHODS: A prospective, multicenter, randomized, parallel group, single-blind clinical trial was performed in 33 patients with ocular hypertension or open angle glaucoma who had not been previously treated. The ocular surface was evaluated prior to and three months after treatment, with a daily drop instillation of one of the three medications. The main outcome measurements included the tear film break-up time, Schirmer's test, Lissamine green staining, the Ocular Surface Disease Index questionnaire, impression cytology using HE and PAS and immunocytochemistry for interleukin-6 and HLA-DR. Ensaiosclinicos.gov.br: UTN - U1111-1129-2872 RESULTS: All of the drugs induced a significant reduction in intraocular pressure. Decreases in the Schirmer's test results were observed with all of the drugs. Decreases in tear-film break-up time were noted with travoprost/timolol and latanoprost/timolol. An increase in the Lissamine green score was noted with travoprost/timolol and bimatoprost/timolol. The Ocular Surface Disease Index score increased after treatment in the travoprost/timolol group. Impression cytology revealed a significant difference in cell-to-cell contact in the same group, an increase in cellularity in all of the groups and an increase in the number of goblet cells in all of the groups. The fixed combinations induced an increase in IL-6 expression in the travoprost/timolol group, in which there was also an increase in HLA-DR expression. CONCLUSIONS: All of the fixed combinations induced a significant reduction in intraocular pressure, and the travoprost/timolol group showed increased expression of the inflammatory markers HLA-DR and interleukin-6. All three tested medications resulted in some degree of deterioration in ...


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Antihypertensive Agents/administration & dosage , Eye/drug effects , Glaucoma, Open-Angle/drug therapy , Ocular Hypertension/drug therapy , Prostaglandins, Synthetic/administration & dosage , Timolol/administration & dosage , Amides/administration & dosage , Cloprostenol/administration & dosage , Cloprostenol/analogs & derivatives , Drug Combinations , HLA-DR Antigens/analysis , Immunohistochemistry , /analysis , Prospective Studies , Prostaglandins F, Synthetic/administration & dosage , Single-Blind Method , Treatment Outcome
8.
Article in English | WPRIM | ID: wpr-243185

ABSTRACT

<p><b>OBJECTIVE</b>To explore the impact of combination use of prostaglandin analogue and cholinergic agonists on main matrix metalloproteinases (MMPs) synthesized by albino rabbit ciliary muscle.</p><p><b>METHODS</b>Normal adult albino rabbits were divided into the control group, 2% pilocarpine group, 0.004% travoprost group and travoprost plus pilocarpine group. Two rabbits in the control group were executed after treated with normal saline for one day. Two rabbits were separately executed on the 7th, 14th and 24th day of the treatment in each drug treated group. In each subgroup ciliary muscle band of 4 eyes was taken and made into homogenate. The MMPs activities of 10 subgroups were assayed by zymography. Bands' intensity which represents the activity of MMPs was measured by the UltraViolet Illumination system.</p><p><b>RESULTS</b>A bright band of MMP-1/2 was showed on each lane at the position corresponding to the molecular weight of 62 kD in the ciliary smooth muscles electrophoresis. When ion Zn and Ca was displaced by MMPs inhibitor EDTA, this bright band disappeared. Compared with the control group, MMP1/2 activity increased by 4.0%, 4.1% and 14.0% after 7, 14 and 24 days of pilocarpine treatment. Corresponding data was 23.2%, 61.7% and 111.5% in the travoprost group and 49.3%, 68.0% and 88.4% in the travoprost plus pilocarpine group.</p><p><b>CONCLUSIONS</b>Pilocarpine has little effect on activity of MMP1/2. Travoprost can increase activity of MMP1/2 gradually. Activity of MMP1/2 is rapidly increased by pilocarpine combined with travoprost, but shows small change with the prolonged treatment.</p>


Subject(s)
Animals , Ciliary Body , Cloprostenol , Pharmacology , Matrix Metalloproteinase 1 , Matrix Metalloproteinase 2 , Muscle, Smooth , Pilocarpine , Pharmacology , Pilot Projects , Rabbits , Travoprost
9.
Indian J Ophthalmol ; 2011 Jan; 59(1): 13-16
Article in English | IMSEAR | ID: sea-136131

ABSTRACT

Context: Peripheral anterior synechiae (PAS; synechiae anterior to functional trabecular meshwork) formation in primary angle-closure glaucoma (PACG) hampers access to uveoscleral outflow. Thus, the role of bimatoprost in such patients with 360° synechiae was evaluated. Aims: To assess efficacy and safety profile of bimatoprost 0.03% in lowering intraocular pressure (IOP) in 360° synechial angle-closure glaucoma patients. Settings and Design: This was a prospective, non-randomized, non-comparative, selective analysis, single-center pilot study. Materials and Methods: A total of 23 eyes of 20 Indian chronic angle-closure glaucoma (CACG) patients with IOP greater than 21 mmHg, 360° PAS and no visual potential in the study eye underwent detailed eye examination. Baseline IOP was measured and YAG peripheral iridotomy was performed for complete angle-closure reconfirmation. Bimatoprost 0.03% was administered for 8 weeks as once-daily evening dose. IOP reduction within treatment group was determined with “paired t-test”. Results: The mean reduction in IOP from baseline to 8 weeks of bimatoprost therapy was 15.3 ± 9.5 mmHg (P < 0.001). The most commonly observed adverse event was conjunctival hyperemia (35%). Bimatoprost was well tolerated in the study. Conclusions: In this study, exclusively involving patients with 360° synechial angle-closure glaucoma and no visual potential, bimatoprost 0.03% treatment demonstrated a statistically significant IOP reduction. Hence, it can be inferred that bimatoprost 0.03% is an efficacious treatment modality in this subgroup of patients for reducing IOP.


Subject(s)
Adult , Aged , Amides/administration & dosage , Amides/adverse effects , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/adverse effects , Cloprostenol/administration & dosage , Cloprostenol/adverse effects , Cloprostenol/analogs & derivatives , Conjunctiva/blood supply , Drug Administration Schedule , Female , Glaucoma, Angle-Closure/drug therapy , Glaucoma, Angle-Closure/physiopathology , Humans , Hyperemia/chemically induced , Intraocular Pressure/drug effects , Male , Middle Aged , Pilot Projects , Prospective Studies , Treatment Outcome
10.
Article in Korean | WPRIM | ID: wpr-15068

ABSTRACT

PURPOSE: To report a case of herpetic keratitis after administration of two different prostaglandin analogues. CASE SUMMARY: A 68-year-old female with a history of herpetic keratitis in her right eye after using latanoprost seven years previous presented with redness, mild ocular pain and tearing in the same eye. She had also been prescribed travoprost eye drops for both eyes for uncontrolled glaucoma one month earlier. The cornea in her right eye showed a dendritic epithelial defect with focal epithelial erosions. Travoprost treatment was discontinued, and the herpetic keratitis recovered completely in ten days with acyclovir ointment and oral agent. No further recurrence was observed in the following six months.


Subject(s)
Acyclovir , Aged , Cloprostenol , Cornea , Eye , Female , Glaucoma , Humans , Keratitis, Herpetic , Ophthalmic Solutions , Prostaglandins F, Synthetic , Prostaglandins, Synthetic , Recurrence , Tears , Travoprost
11.
Chinese Medical Journal ; (24): 1417-1421, 2010.
Article in English | WPRIM | ID: wpr-241768

ABSTRACT

<p><b>BACKGROUND</b>Travoprost has been widely used for the treatment of patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The aim of this study was to evaluate the intraocular pressure (IOP) lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients.</p><p><b>METHODS</b>This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy (due to either inadequate efficacy or safety issues) as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. in both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. IOP measurements were performed at the same time of day at the follow-up visits.</p><p><b>RESULTS</b>For patients transitioned to travoprost, mean IOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were: latanoprost, (4.3 +/- 4.6) mmHg; beta-blocker, (6.3 +/- 4.0) mmHg; alpha-agonist, (7.5 +/- 4.3) mmHg; topical carbonic anhydrase inhibitors, (8.0 +/- 4.9) mmHg. All mean IOP changes from baseline were statistically significant (P < 0.001). No treatment-related serious adverse events were reported in this study.</p><p><b>CONCLUSIONS</b>In patients treated with other hypotensive medications or untreated, the IOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate IOP control. Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension.</p>


Subject(s)
Aged , Antihypertensive Agents , Pharmacology , Therapeutic Uses , Cloprostenol , Pharmacology , Therapeutic Uses , Female , Glaucoma, Open-Angle , Drug Therapy , Humans , Intraocular Pressure , Male , Middle Aged , Ocular Hypertension , Drug Therapy , Travoprost , Treatment Outcome
12.
Arq. bras. oftalmol ; 72(1): 13-17, jan.-fev. 2009. graf, tab
Article in Portuguese | LILACS | ID: lil-510014

ABSTRACT

OBJETIVO: Avaliar, através da curva diária de pressão intraocular (CDPo), a eficácia do latanoprosta (L) e do travoprosta (T) como monoterapia e do L e T associados ao maleato de timolol 0,5 por cento (LTim 0,5 por cento e TTim 0,5 por cento) em pacientes glaucomatosos. MÉTODOS: Análise retrospectiva da curva diária de pressão intraocular de pacientes glaucomatosos em uso de L ou T ou das associações LTim 0,5 por cento e TTim 0,5 por cento. Foram excluídos os pacientes que não usaram a(s) medicação(ões) de maneira correta na curva diária de pressão intraocular e aqueles que estavam em uso de L ou T associado a outro hipotensor qão o timolol 0,5 por cento ou em uso de mais de dois colírios antiglaucomatosos. Foram analisados, em cada grupo, a pressão média (Pm) e a variabilidade (V) e seus respectivos desvios padrões. Utilizou-se o programa SPSS 11.0 na análise estatística. Raça, idade, sexo e tipo de glaucoma não foram critérios para a inclusão ou a exão dos pacientes. RESULTADOS: Foram incluídos 75 pacientes (142 olhos) com idade média de 61,7 anos, sendo 33 (44,0 por cento) do sexo masculino e 42 (56,0 por cento) do feminino. Treze pacientes (26 olhos - 18,3 por cento) usavam L; 18 pacientes (33 olhos - 23,2 por cento) usavam T; 18 pacientes (32 olhos - 22,5 por cento) estavam em tratamento com LTim 0,5 por cento e 26 pacientes (51 olhos - 35,9 por cento) usavam a associação TTim 0,5 por cento. Sessenta e nove pacientes (92,0 por cento) eram portadores de glaucoma crônico simples; 5 (6,7 por cento) de glaucoma congênito e 1 (1,3 por cento) de glaucoma pós-pseudofacia. Nos grupos L e T, os valores da Pm foram 15,2 (± 4,2) mmHg e 14,8 (±3,2) mmHg e os da V foram 2,0 (± 1,2) e 3,2 (± 1,9), respectivamente. Nos grupos LTim 0,5 por cento e TTim 0,5 por cento, os valores da Pm foram 14,9 (± 2,2) mmHg e 15,0 (±3,2) mmHg e os da V foram 2,4 (± 1,2) e 2,8 (± 1,6), respectivamente. Não houve diferença estatisticamente significativa na Pm entre ...


PURPOSE: To assess the efficacy of latanoprost (L) and travoprost (T) as monotherapy as well as both drugs associated with 0.5 percent timolol maleate twice a day regarding the daily curve of intraocular pressure (DCPo) with the measurement of intraocular pressure (IOP) at 6 am in bed. METHODS: Retrospective study analyzing the daily curve of intraocular pressure of patients treated with L or T with or without 0.5 percent Tim. Patients who did not correctly follow the treatment were excluded. We also excluded the patients who used the prostaglandin analog associated with any other antiglaucomatous drug different from 0.5 percent Tim and those who were treated with more than two antiglaucomatous drugs. Statistical analysis was made through the SPSS 11.0 program calculating mean intraocular pressure (Pm), variability (V), p value and standard deviation. Ethnic aspects or type of glaucoma were no criteria of inclusion or exclusion in this study. RESULTS: Seventy-five patients (142 eyes) were included. The average age was 61.7 years. Thirty-three (44.0 percent) patients were male and 42 (56.0 percent) were female. Thirteen patients (26 eyes 18.3 percent) used L, 18 patients (33 eyes - 23.2 percent) were treated with T, 18 patients (32 eyes - 22.5 percent) used latanoprost and 0.5 percent timolol (L 0.5 percentTim) and 26 patients (51 eyes - 35.9 percent) used travoprost and 0.5 percent timolol (T 0.5 percentTim). Chronic simple glaucoma was the most common type (92.0 percent), followed by congenital glaucoma (6.7 percent) and glaucoma secondary to cataract surgery (1.3 percent). Pm was 15.2 (± 4.2) mmHg among those treated with L and 14.8 (± 3.2) mmHg among the T users. Those patients showed a V of 2.0 (± 1.2) and 3.2 (± 1.9). In the group of L 0.5 percentTim and T 0.5 percentTim the Pm and V were 14.9 (± 2.2) mmHg, 15.0 (± 3.2) mmHg, 2.4 (± 1.2) and 2.8 (± 1.6) respectively. No statistical significant difference was found in the Pm neither ...


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Antihypertensive Agents/administration & dosage , Cloprostenol/analogs & derivatives , Glaucoma/drug therapy , Intraocular Pressure/drug effects , Prostaglandins F, Synthetic/administration & dosage , Timolol/administration & dosage , Antihypertensive Agents/therapeutic use , Circadian Rhythm , Cloprostenol/administration & dosage , Cloprostenol/therapeutic use , Drug Therapy, Combination , Prostaglandins F, Synthetic/therapeutic use , Retrospective Studies , Timolol/therapeutic use , Young Adult
13.
Article in Korean | WPRIM | ID: wpr-11389

ABSTRACT

PURPOSE: To evaluate the effects of prostaglandin analogues on the corneal thickness of patients with primary open-angle glaucoma (POAG) or normal tension glaucoma (NTG). METHODS: This study included 130 eyes of 65 patients who were diagnosed with POAG or NTG. All patients were divided into two groups; one group received prostaglandin analogues, while the other group received alternative ocular hypotensive eyedrops. Corneal thickness, best corrected visual acuity, and flare in the anterior chamber were measured and compared before treatment and at least 24 months (mean: 27 months) after treatment. RESULTS: The mean decrease in corneal thickness was statistically significant in the group using prostaglandin analogues, but not in the control group. Among the various prostaglandin analogues used, travoprost and latanoprost decreased mean corneal thickness, but bimatoprost had no effect. Best corrected visual acuity, refraction power, and flare in the anterior chamber did not change significantly in either group of patients when ocular hypotensive eyedrops were used. CONCLUSIONS: Prostaglandin analogues lower intraocular pressure and decrease corneal thickness if used over a 24 months.


Subject(s)
Amides , Anterior Chamber , Cloprostenol , Eye , Glaucoma, Open-Angle , Humans , Intraocular Pressure , Low Tension Glaucoma , Ophthalmic Solutions , Prostaglandins F, Synthetic , Prostaglandins, Synthetic , Visual Acuity , Bimatoprost , Travoprost
14.
Arq. bras. med. vet. zootec ; 60(6): 1323-1328, dez. 2008. ilus, tab
Article in Portuguese | LILACS | ID: lil-506540

ABSTRACT

Avaliou-se a eficácia da dose de 0,10 ou de 0,25mg de gonadorelina nas taxas de ovulação e de sincronização no protocolo Ovsynch e de 150mcg de D-cloprostenol ou 0,530mg de cloprostenol sódico na regressão do corpo lúteo (CL) de sete dias e de todos os CL. Foram utilizadas 136 vacas lactantes da raça Holandesa, com média de produção de leite de 23,75,8kg/dia, com 138,4±72,0 dias em lactação. As vacas foram distribuídas aleatoriamente em quatro grupos, de acordo com a dose de gonadorelina e o tipo da prostaglandina. As taxas de ovulação e de sincronização foram de 52,9 por cento e 80,9 por cento para 0,10mg de gonadorelina e de 57,4 por cento e 80,9 por cento para 0,25mg de gonadorelina, respectivamente. A taxa de regressão do CL de sete dias foi de 97,1 por cento para o D-cloprostenol e de 97,5 por cento para o cloprostenol sódico. A taxa de prenhez não foi influenciada pelos tratamentos, mas foi influenciada pela taxa de ovulação à primeira aplicação de gonadorelina, 16,0 por cento vs. 6,6 por cento para as vacas que ovularam e não ovularam, respectivamente. Conclui-se que 0,10mg de gonadorelina foi eficiente e ambas prostaglandinas podem ser usadas em protocolos de sincronização da ovulação.


The efficacy of 150mcg D-cloprostenol or 0.530mg cloprostenol sodium on the 7- day corpus luteum (CL) regression rate, and of two doses of gonadorelin, 0.10mg vs. 0.25mg, on the ovulation and synchronization rates during the Ovsynch protocol were evaluated. Lactating Holstein cows (n=136), producing 23.75.8kg milk/d and 138.4±72.0 days in milk were randomly assigned to four groups, according to dose of gonadorelin and prostaglandin type. No effect of the products and doses tested on conception rate were observed. The ovulation and synchronization rates using 0.10mg or 0.25mg of gonadorelin were 52.9 percent and 80.9 percent vs. 57.4 percent and 80.9 percent, respectively. The CL regression rates in cows ovulating after the first GnRH using D-cloprostenol or cloprostenol sodium were 97.1 percent and 97.5 percent, respectively. The pregnancy rate was not affected by treatment, but by ovulation rate after the first injection of GnRH. The pregnancy rates were 16.0 percent and 6.6 percent for ovulated and non ovulated cows, respectively. The results suggest that 0.10mg dose of gonadorelin was efficient and both prostaglandins can be used in synchronization of ovulation protocols.


Subject(s)
Animals , Female , Cattle , Cloprostenol/administration & dosage , Gonadotropin-Releasing Hormone/administration & dosage , Gonadotropin-Releasing Hormone/analysis , Prostaglandins/administration & dosage , Prostaglandins/analysis , Prostaglandins/physiology , Estrus Synchronization , Estrus Synchronization/methods
15.
Arq. bras. oftalmol ; 71(5): 684-688, set.-out. 2008. graf, tab
Article in Portuguese | LILACS | ID: lil-497221

ABSTRACT

OBJETIVO: Investigar se há diferença no peso e volume das gotas de colírios análogos das prostaglandinas em ângulos de gotejamento de 45º e 90º com relação ao plano horizontal. MÉTODOS: Foi realizado estudo experimental utilizando os colírios latanoprosta, travoprosta e bimatoprosta, pelo qual se gotejava as soluções com angulação de 45º e 90º. Estes colírios foram escolhidos em virtude do seu uso rotineiro em oftalmologia e do seu custo. A primeira gota e dez gotas seguintes foram pesadas em ângulo de 45º e 90º. A análise estatística foi realizada por meio do programa SPSS® 12.0 (Microsoft), utilizando o teste de variância ANOVA, sendo considerada diferença estatisticamente significante um valor P<0,001. RESULTADOS: Verificou-se que há diferença no peso, e conseqüentemente no volume, das gotas instiladas a 45º e a 90º dos colírios de travoprosta e bimatoprosta. Para o colírio travoprosta o gotejo a 45º produz uma gota menor que em 90º. O inverso ocorre para o colírio de bimatoprosta. Já para o colírio de latanoprosta, não houve diferença estatisticamente significante. CONCLUSÕES: Como houve diferença estatística no peso das gotas de dois colírios análogos das prostaglandinas e em outro não se verificou esta variação, - e como este possui relação direta com o volume - infere-se que devemos ser críticos diante de estimativas de custo ou duração da terapia com base no gotejamento dos colírios considerando número de gotas por frasco e volume.


PURPOSE: To investigate if there is any difference in volume and drop weight of prostaglandin analogs when adopting drip angles of 45º and 90º, regarding a horizontal line. METHODS: An experimental study was conducted using the follow ophthalmic solutions: latanoprost, travoprost and bimatoprost. In this study the ophthalmic solutions were dripped according to an angle of 45º or 90º. Prostaglandin analogs were chosen due to their common use in ophthalmology and their cost. The first drop and other ten drops were weighed, alternating the drip angle (45º or 90º). Statistical analysis was done with SPSS® 12.0 (Microsoft), using quantitative comparisons with the ANOVA test. An odds value (P) below 0.001 was considered a statistical significant difference. RESULTS: We verified differences in weight and size of the travoprost and bimatoprost drops instilled at 45º and 90º. The drip at 45º produces a smaller drop of travoprost (P<0.001), and the inverse occurs for bimatoprost. There were no statistical significant differences in weight of latanoprost drops according to the instillation angle. CONCLUSIONS: Once there was statistical difference in weight - which has direct relationship with size - of the drops of two kinds of prostaglandin analogs and in another one we did not observe this variation, we infer that cost and therapy duration estimates should be analyzed carefully, especially if this kind of drip measure is used.


Subject(s)
Humans , Antihypertensive Agents/administration & dosage , Prostaglandins F, Synthetic/administration & dosage , Amides/administration & dosage , Antihypertensive Agents/economics , Cloprostenol/administration & dosage , Cloprostenol/analogs & derivatives , Glaucoma/drug therapy , Instillation, Drug , Ophthalmic Solutions/administration & dosage , Ophthalmic Solutions/economics , Prostaglandins F, Synthetic/economics
16.
J Indian Med Assoc ; 2008 May; 106(5): 312, 346
Article in English | IMSEAR | ID: sea-104306

ABSTRACT

Carotid cavernous sinus fistula is abnormal communications between the carotid arterial system and the venous cavernous sinus. Carotid cavernous sinus fistula can develop either because of trauma or spontaneous causes. Spontaneous carotid cavernous sinus fistula is often associated with a pre-existing aneurysm in the intracavernous portion of internal carotid artery. However, these fistulas may be congenital arteriovenous connections that open spontaneously in the settings of collagen vascular disease, atherosclerosis, hypertension, or may develop in females during peripartum period. A case of spontaneous carotid cavernous sinus fistula in a young adult male who presented with pulsating exophthalmos and secondary glaucoma is presented. Characteristic features of arteriovenous fistula--bruit, thrill, corkscrew episcleral vessels were present. Radiological investigations were done to confirm the diagnosis. Transvenous embolisation was done to close the fistula.


Subject(s)
Adult , Amides/therapeutic use , Antihypertensive Agents/therapeutic use , Carotid-Cavernous Sinus Fistula/complications , Cloprostenol/analogs & derivatives , Exophthalmos/diagnosis , Glaucoma/diagnosis , Humans , Male , Timolol/therapeutic use
17.
Veterinary Medical Journal. 2008; 56 (3): 297-306
in English | IMEMR | ID: emr-90761

ABSTRACT

The objective of this trial was to compare the efficacy of long-term and short-term progesterone treatments on induction of estrus and pregnancy rate in Rahmani ewes during non-breeding and breeding seasons. Twenty-four animals were randomly grouped for two treatments with intravaginal progesterone device: Group A] during breeding season and Group B] during non-breeding season. Furthermore, both groups were subdivided into two treatments: Al and BI for short-treatment [7 days] and A2 and B2 for long-treatment [12 days]. The progesterone treatment was a vaginal sponge containing 40 mg medroxy progesterone acetate [MAP]. Equine chorionic gonadotrophin [eCG] and cloprostenol [PGF2 alpha] were intramuscularly administered to all ewes at the time of sponge removal. After the detection of estrus, the animals were hand-mated naturally. During the breeding season, mean percentages of estrus and pregnancy were 100% and 83.33%, respectively in both the short-term and long-term treated groups. During the non-breeding season, the average values of estrus were 100% in short-term and 100% for long-term progesterone treatment, but the pregnancy rates were 66.67 and 50.00% in the short- and long-term treated groups, respectively. The treatment with progesterone for short-term [7 days] was effective to induce estrus in sheep during both breeding and non-breeding seasons


Subject(s)
Animals , Estrus , Progesterone , Breeding , Estrus Detection , Pregnancy Rate , Progesterone/administration & dosage , Estrus , Cloprostenol , Chorionic Gonadotropin
18.
Arq. bras. oftalmol ; 70(6): 910-916, nov.-dez. 2007. ilus, tab
Article in English | LILACS | ID: lil-474093

ABSTRACT

PURPOSE: To compare histological changes induced by antiglaucoma medications in the rabbit conjunctiva. METHODS: Fifty New Zealand rabbits were divided in 5 groups of 10 animals. The left eyes were treated daily with one drop of bimatoprost 0.03 percent, travoprost 0.004 percent, latanoprost 0.005 percent, timolol maleate 0.5 percent or artificial tears containing benzalkonium chloride (BAK) for 30 days. The right eyes served as controls. Superior limbic conjunctival biopsies were performed at the 8th and 30th day in 5 rabbits of each group. The conjunctiva was fixed with 10 percent formaldehyde, followed by HE and PAS staining. Morphohistometric quantitative analyses were performed to evaluate the following parameters: inflammatory infiltrate, epithelial thickness, number of goblet cells, diameter and number of blood vessels. RESULTS: At the 8th and 30th posttreatment days, all groups, except one that received artificial tears, exhibited a diffuse inflammatory infiltrate, composed by lymphocytes and neutrophils, which was denser in the timolol group than in the prostaglandin (PG) analogues groups. At the 30th day, the timolol group also showed an increased subepithelial collagen density and a significant increase in epithelial thickness (p=0.0035). The goblet cell density was significantly increased at the 8th day in the group treated with travoprost (p=0.0006), and at the 30th day in those treated with bimatoprost (p=0.0021) and latanoprost (p=0.009). CONCLUSIONS: Although a moderate, diffuse inflammatory infiltrate was observed in PG-treated eyes, no changes in conjunctival epithelial thickness or subconjunctival collagen density were observed with these medications, suggesting that these drugs induce fewer changes than timolol maleate in the rabbit conjunctiva.


OBJETIVOS: Comparar alterações histológicas induzidas por medicação anti-glaucomatosa na conjuntiva de coelhos. MÉTODOS: Cinqüenta coelhos da raça Nova Zelândia foram divididos em 5 grupos de 10 animais. Os olhos esquerdos foram tratados com uma gota diária de bimatoprosta 0,03 por cento, travoprosta 0,004 por cento, latanoprosta 0,005 por cento, maleato de timolol 0,5 por cento ou lágrimas artificiais contendo cloreto de benzalcônio (BAK) por 30 dias. Os olhos direitos serviram como controles. Foram realizadas biópsias conjuntivais límbicas superiores no 8º e 30º dias em 5 coelhos de cada grupo. A conjuntiva foi fixada com formaldeído 10 por cento, seguido por coloração de HE e PAS. Foi realizada análise quantitativa morfohistométrica para avaliar os seguintes parâmetros: infiltrado inflamatório, espessura epitelial, número de células caliciformes, diâmetro e número de vasos sanguíneos. RESULTADOS: No 8º e 30º dias de tratamento, todos os grupos, exceto aquele que recebeu lágrimas artificiais, exibiram infiltrado inflamatório difuso, composto por linfócitos e neutrófilos, sendo mais denso no grupo timolol do que nos grupos dos análogos de prostaglandinas. No 30º dia, o grupo timolol apresentou um aumento na densidade de colágeno subepitelial e um aumento significativo da espessura epitelial (p=0,0035). A densidade de células caliciformes aumentou significativamente no 8º dia no grupo tratado com travoprosta (p=0,0006), e no 30º dia nos grupos tratados com bimatoprosta (p=0,0021) e latanoprosta (p=0,009). CONCLUSÕES: Embora tenha sido observado um infiltrado inflamatório difuso e moderado nos olhos tratados com análogos de prostaglandinas, não houve alterações na espessura epitelial conjuntival ou densidade colágena subepitelial com essas medicações, sugerindo que essas drogas induzem menores alterações que o maleato de timolol na conjuntiva de coelhos.


Subject(s)
Animals , Female , Rabbits , Antihypertensive Agents/adverse effects , Conjunctiva/drug effects , Ophthalmic Solutions/administration & dosage , Prostaglandins, Synthetic/adverse effects , Timolol/adverse effects , Analysis of Variance , Amides/administration & dosage , Amides/adverse effects , Antihypertensive Agents/administration & dosage , Biopsy , Benzalkonium Compounds/administration & dosage , Benzalkonium Compounds/adverse effects , Cloprostenol/administration & dosage , Cloprostenol/adverse effects , Cloprostenol/analogs & derivatives , Conjunctiva/pathology , Disease Models, Animal , Goblet Cells/drug effects , Goblet Cells/pathology , Prostaglandins F, Synthetic/administration & dosage , Prostaglandins F, Synthetic/adverse effects , Prostaglandins, Synthetic/administration & dosage , Staining and Labeling , Time Factors , Timolol/administration & dosage
19.
Arq. bras. med. vet. zootec ; 59(5): 1089-1096, out. 2007. graf, tab
Article in Portuguese | LILACS | ID: lil-471187

ABSTRACT

Caracterizaram-se o padrão de crescimento folicular e a função lútea ao longo do ciclo estral em vacas da raça Guzerá (n=5), multíparas, não-lactantes. Os animais utilizados apresentavam idade e condição corporal semelhantes e peso corporal médio de 518± 48.5kg. A dinâmica folicular foi monitorada diariamente a partir do dia da ovulação, durante dois ciclos consecutivos, utilizando-se um aparelho de ultra-sonografia equipado com uma probe linear retal de 5MHz. Amostras de sangue foram coletadas a cada 48h, a partir do momento da ovulação, durante os dois ciclos. O primeiro ciclo foi sincronizado pela administração de um luteolítico (cloprostenol), e o segundo foi natural. Os folículos foram identificados e mensurados; e os dados obtidos, registrados em função do dia do ciclo. O comprimento do ciclo estral foi de 19,10± 1,86 dias. Observou-se maior incidência de ciclos com três ondas de crescimento folicular (50 por cento), mas ciclos com duas (37,5 por cento) ou quatro ondas (12,5 por cento) também foram identificados. O diâmetro máximo dos folículos dominantes não ovulatórios foi de 11,60± 2,37 mm, e dos folículos ovulatórios de 14,4± 0,5 mm. A taxa de crescimento dos folículos dominantes da primeira, segunda, terceira e quarta onda foi de 1,48± 0,60; 0,81± 0,13; 1,10± 0,27 e 1,33mm/dia, respectivamente. A concentração máxima de progesterona no diestro foi de 5,50± 0,92ng/ml. A raça Guzerá apresenta características da dinâmica folicular semelhantes àquelas observadas em outras raças zebuínas, como a tendência ao maior número de ondas de crescimento associadas à menor taxa de crescimento, diâmetro máximo e persistência dos folículos dominantes das ondas intermediárias


The follicular growth pattern and luteal function during the estrous cycle were studied using multiparous, non-lactating Guzerá cows (n=5). The animals presented similar age, body score condition, and mean body weight of 518 ± 48.5kg. Follicular dynamics was daily monitored between ovulations during two consecutive estrous cycles, using an ultrasound device equipped with a linear rectal 5MHz transducer. Blood samples were collected each 48h after ovulation, during the evaluated cycles. The first cycle was synchronized using a luteolytic agent (cloprostenol), and the second estrous cycle was natural. Follicles were identified and measured, and data were individually recorded according to the day of the cycle. The mean length of the cycles was 19.10 ± 1.86 days. There was a higher incidence of cycles presenting three follicular growth waves (50 percent), but cycles presenting two (37.5 percent) or three (12.5 percent) waves were also observed. The maximum diameter of non-ovulatory follicles was 11.60± 2.37mm, and that of ovulatory follicles was 14.40± 0.50mm. The growth rate of dominant follicles during the first, second, third and fourth waves were 1.48 ± 0.60; 0.81 ± 0.13; 1.10 ± 0.27 and 1.33mm/day, respectively. Progesterone maximum concentration during diestrus was 5.50± 0.92ng/ml. These results show that the Guzera breed presents characteristics of the follicular dynamics similar to those observed in other Zebu breeds, like the trend to a higher number of follicular waves associated with lower growth rate, maximum diameter and persistence of the dominant follicles emerging during non-ovulatory waves


Subject(s)
Animals , Female , Cattle , Cattle/microbiology , Corpus Luteum , Cloprostenol/administration & dosage , Ovarian Follicle/physiology , Ultrasonography , Estrous Cycle/physiology
20.
Arq. bras. med. vet. zootec ; 58(3): 367-372, jun. 2006. tab
Article in Portuguese | LILACS | ID: lil-443590

ABSTRACT

Doze cabras nulíparas da raça Toggenburg foram distribuídas em dois tratamentos (T1 e T2) para indução do estro. O T1 (n=6) consistiu na inserção da esponja impregnada com 60mg de acetato de medroxiprogesterona, associado à aplicação de 50æg do análogo sintético d-cloprostenol (PGF). No quarto dia, foram aplicadas 250UI de gonadotropina coriônica eqüina (eCG) e, no quinto, a esponja foi retirada. O T2 (n=6) diferiu somente quanto ao dispositivo empregado, que foi o CIDR-G®. Seis cabras do T1 e seis do T2 entraram em estro depois da retirada dos dispositivos, sendo que 83,3 (5/6) e 33,3 por cento (2/6) ficaram gestantes em T1 e T2, respectivamente. O intervalo da retirada do dispositivo ao início do estro não diferiu entre tratamentos (P>0,05). As características ovulatórias não foram influenciadas pelos tratamentos. O intervalo da retirada do dispositivo à ovulação, para ambos os protocolos de indução do estro, não diferiu (P>0,05) entre tratamentos. Ambos os dispositivos foram eficientes em induzir o estro.


Twelve Toggenburg breed nuliparous female goats were randomly assigned to two treatments intended to induce estrus. On day zero, animals on T1 (n=6) were treated with an intravaginal sponge impregnated with 60mg of medroxyprogesterone acetate plus 50æg of PGF analogue. The T1 goats received eCG (250IU) on day 4, and on day 5 the sponge was removed. The T2 goats (n=6) received CIDR-G® as intravaginal sponge plus 50mg of PGF analogue. All goats expressed behavioral estrus, and the pregnancy rates were 83.3 (5/6) and 33.3 percent (2/6) for T1 and T2, respectively. The interval from withdrawal of the device to onset of estrus did not differ between treatments (P>0.05). Ovulatory traits also were not affected by treatments. The interval between CIDR-G® removal and ovulation for T1 and T2 goats were similar (P>0.05). Both sponge and CIDR-G were equally efficient in inducing the estrus behavior in goats.


Subject(s)
Animals , Female , Cloprostenol/administration & dosage , Estrus/physiology , Goats , Chorionic Gonadotropin/administration & dosage , Medroxyprogesterone/administration & dosage , Ovulation/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL